Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone [Yahoo! Finance]
Soligenix, Inc. (SNGX)
NASDAQ:AMEX Investor Relations:
soligenix.com/investors
Company Research
Source: Yahoo! Finance
NEW YORK and PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PCG Digital -- Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company, is making significant strides in the treatment of Cutaneous T-Cell Lymphoma (CTCL) with its investigational drug, HyBryte™. In an exclusive interview, PCG Digital speaks with Dr. Brian Poligone, Director of the Rochester Skin Lymphoma Medical Group and Principal Investigator for Soligenix's comparative study, who shares insights on the promising advancements. Key Highlights from the Interview: Need for Rapid and Safe Treatments: Given that CTCL is incurable but manageable with chronic treatment, there is a critical need for therapies that can induce rapid remission and be safely used over long periods. Comparative Study Findings: Dr. Poligone discusses the HPN-CTCL-04 study , which compared HyBryte™ to Valchlor ® . Preliminary results indicate that HyBryte™ is both safe and effective. The study used standard CTCL measurements to
Show less
Read more
Impact Snapshot
Event Time:
SNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNGX alerts
High impacting Soligenix, Inc. news events
Weekly update
A roundup of the hottest topics
SNGX
News
- Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024PR Newswire
- Soligenix Receives European Patent for Improved Production of Synthetic HypericinPR Newswire
- Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire
- Soligenix Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
- Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial ResultsPR Newswire
SNGX
Sec Filings
- 8/16/24 - Form 424B5
- 8/16/24 - Form 8-K
- 8/9/24 - Form 424B3
- SNGX's page on the SEC website